FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1990814650> ?p ?o ?g. }

• W1990814650 endingPage "1838" @default.
• W1990814650 startingPage "1825" @default.
• W1990814650 abstract "Data on efficacy and safety of azacitidine in acute myeloid leukemia (AML) with >30 % bone marrow (BM) blasts are limited, and the drug can only be used off-label in these patients. We previously reported on the efficacy and safety of azacitidine in 155 AML patients treated within the Austrian Azacitidine Registry (clinicaltrials.gov identifier NCT01595295). We herein update this report with a population almost twice as large (n = 302). This cohort included 172 patients with >30 % BM blasts; 93 % would have been excluded from the pivotal AZA-001 trial (which led to European Medicines Agency (EMA) approval of azacitidine for high-risk myelodysplastic syndromes (MDS) and AML with 20–30 % BM blasts). Despite this much more unfavorable profile, results are encouraging: overall response rate was 48 % in the total cohort and 72 % in patients evaluable according to MDS-IWG-2006 response criteria, respectively. Median OS was 9.6 (95 % CI 8.53–10.7) months. A clinically relevant OS benefit was observed with any form of disease stabilization (marrow stable disease (8.1 months), hematologic improvement (HI) (9.7 months), or the combination thereof (18.9 months)), as compared to patients without response and/or without disease stabilization (3.2 months). Age, white blood cell count, and BM blast count at start of therapy did not influence OS. The baseline factors LDH >225 U/l, ECOG ≥2, comorbidities ≥3, monosomal karyotype, and prior disease-modifying drugs, as well as the response-related factors hematologic improvement and further deepening of response after first response, were significant independent predictors of OS in multivariate analysis. Azacitidine seems effective in WHO-AML, including patients with >30 % BM blasts (currently off-label use). Although currently not regarded as standard form of response assessment in AML, disease stabilization and/or HI should be considered sufficient response to continue treatment with azacitidine." @default.
• W1990814650 created "2016-06-24" @default.
• W1990814650 creator A5002055787 @default.
• W1990814650 creator A5007229434 @default.
• W1990814650 creator A5011161370 @default.
• W1990814650 creator A5011779787 @default.
• W1990814650 creator A5014330678 @default.
• W1990814650 creator A5018155083 @default.
• W1990814650 creator A5021490305 @default.
• W1990814650 creator A5027961300 @default.
• W1990814650 creator A5028913166 @default.
• W1990814650 creator A5035438610 @default.
• W1990814650 creator A5036755760 @default.
• W1990814650 creator A5039285562 @default.
• W1990814650 creator A5039994927 @default.
• W1990814650 creator A5043678326 @default.
• W1990814650 creator A5053254720 @default.
• W1990814650 creator A5060733373 @default.
• W1990814650 creator A5068530407 @default.
• W1990814650 creator A5071708178 @default.
• W1990814650 creator A5072949561 @default.
• W1990814650 creator A5080057087 @default.
• W1990814650 date "2014-06-21" @default.
• W1990814650 modified "2023-10-17" @default.
• W1990814650 title "Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group" @default.
• W1990814650 cites W1534965621 @default.
• W1990814650 cites W1572539757 @default.
• W1990814650 cites W1645524462 @default.
• W1990814650 cites W1764888106 @default.
• W1990814650 cites W187238933 @default.
• W1990814650 cites W1971274012 @default.
• W1990814650 cites W1992607388 @default.
• W1990814650 cites W1999688002 @default.
• W1990814650 cites W2003763899 @default.
• W1990814650 cites W2021056610 @default.
• W1990814650 cites W2029529782 @default.
• W1990814650 cites W2029595590 @default.
• W1990814650 cites W2032699876 @default.
• W1990814650 cites W2080537509 @default.
• W1990814650 cites W2110893339 @default.
• W1990814650 cites W2115937548 @default.
• W1990814650 cites W2117446917 @default.
• W1990814650 cites W2118771330 @default.
• W1990814650 cites W2121603250 @default.
• W1990814650 cites W2128812336 @default.
• W1990814650 cites W2129510594 @default.
• W1990814650 cites W2144244435 @default.
• W1990814650 cites W2157287007 @default.
• W1990814650 cites W2159507916 @default.
• W1990814650 cites W2567848934 @default.
• W1990814650 cites W4376595466 @default.
• W1990814650 doi "https://doi.org/10.1007/s00277-014-2126-9" @default.
• W1990814650 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4176957" @default.
• W1990814650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24951123" @default.
• W1990814650 hasPublicationYear "2014" @default.
• W1990814650 type Work @default.
• W1990814650 sameAs 1990814650 @default.
• W1990814650 citedByCount "81" @default.
• W1990814650 countsByYear W19908146502014 @default.
• W1990814650 countsByYear W19908146502015 @default.
• W1990814650 countsByYear W19908146502016 @default.
• W1990814650 countsByYear W19908146502017 @default.
• W1990814650 countsByYear W19908146502018 @default.
• W1990814650 countsByYear W19908146502019 @default.
• W1990814650 countsByYear W19908146502020 @default.
• W1990814650 countsByYear W19908146502021 @default.
• W1990814650 countsByYear W19908146502022 @default.
• W1990814650 countsByYear W19908146502023 @default.
• W1990814650 crossrefType "journal-article" @default.
• W1990814650 hasAuthorship W1990814650A5002055787 @default.
• W1990814650 hasAuthorship W1990814650A5007229434 @default.
• W1990814650 hasAuthorship W1990814650A5011161370 @default.
• W1990814650 hasAuthorship W1990814650A5011779787 @default.
• W1990814650 hasAuthorship W1990814650A5014330678 @default.
• W1990814650 hasAuthorship W1990814650A5018155083 @default.
• W1990814650 hasAuthorship W1990814650A5021490305 @default.
• W1990814650 hasAuthorship W1990814650A5027961300 @default.
• W1990814650 hasAuthorship W1990814650A5028913166 @default.
• W1990814650 hasAuthorship W1990814650A5035438610 @default.
• W1990814650 hasAuthorship W1990814650A5036755760 @default.
• W1990814650 hasAuthorship W1990814650A5039285562 @default.
• W1990814650 hasAuthorship W1990814650A5039994927 @default.
• W1990814650 hasAuthorship W1990814650A5043678326 @default.
• W1990814650 hasAuthorship W1990814650A5053254720 @default.
• W1990814650 hasAuthorship W1990814650A5060733373 @default.
• W1990814650 hasAuthorship W1990814650A5068530407 @default.
• W1990814650 hasAuthorship W1990814650A5071708178 @default.
• W1990814650 hasAuthorship W1990814650A5072949561 @default.
• W1990814650 hasAuthorship W1990814650A5080057087 @default.
• W1990814650 hasBestOaLocation W19908146501 @default.
• W1990814650 hasConcept C104317684 @default.
• W1990814650 hasConcept C126322002 @default.
• W1990814650 hasConcept C143998085 @default.
• W1990814650 hasConcept C150194340 @default.
• W1990814650 hasConcept C185592680 @default.
• W1990814650 hasConcept C190727270 @default.
• W1990814650 hasConcept C194409129 @default.
• W1990814650 hasConcept C2776012956 @default.

• next